N-BOC-3-环己基-D-丙氨酸 | 127095-92-5

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-BOC-3-环己基-D-丙氨酸
• 中文别名: BOC-D-CHA-OH水合物；Boc-D-环己基丙氨；(R)-2-叔丁氧羰基氨基-3-环己基丙酸；BOC-D-环己基丙氨酸；Boc-D-环己基丙氨酸
• 英文名称: N-tert-butoxycarbonyl-D-cyclohexylalanine
• 英文别名: (2R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid；(R)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid；Boc-D-Cha-OH；Boc-D-cyclohexylalanine-OH；Boc-D-cyclohexylalanine；(2R)-3-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 127095-92-5
• 化学式: C₁₄H₂₅NO₄
• 分子量: 271.357
• InChiKey: MSZQAQJBXGTSHP-LLVKDONJSA-N

物化性质

• 熔点：
  64-67 °C
• 沸点：
  420.4±28.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-D-Cha-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-D-Cha-OH
CAS number: 127095-92-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H25NO4
Molecular weight: 271.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-BOC-3-环己基-D-丙氨酸 在 盐酸 、 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醚 、 二氯甲烷 、 水 为溶剂， 生成 methyl (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxybutanoate
  参考文献：
  名称：

  Design and synthesis of β-amino-α-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth

  摘要：

  The rational design and synthesis of beta-amino-alpha-hydroxy amide derivatives as reversible inhibitors of methionine aminopeptidase-2 (MetAP2) with anti-proliferative activity against human umbilical vein endothelial cells (HUVECs) is described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.004
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 D-Β环己基丙氨酸盐酸盐 在 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 以100%的产率得到N-BOC-3-环己基-D-丙氨酸
  参考文献：
  名称：

  大环化合物Ac-Phe- [Orn-Pro-D-Cha-Trp-Arg]（一种有效的新型抗炎药）的收敛性溶液相合成。

  摘要：

  在过去的十年中，相对较少的环肽进入了制药市场，大多数是通过发酵而不是合成制备的。通常，这类化合物是通过固相方法以毫克级为研究目的合成的，但是如果要实现大环肽模拟物的潜力，则需要设计和优化低成本的大规模溶液相合成方法，以提供足够的用于临床前，临床和商业用途的数量。在这里，我们描述了人类C5a受体的第一个报道的高效，选择性和口服活性拮抗剂的廉价，中等规模的溶液相合成方法。这种化合物Ac-Phe [Orn-Pro-d-Cha-Trp-Arg]，称为3D53，是人血浆蛋白C5a的大环肽模拟物，在许多人类疾病的动物模型中显示出出色的抗炎活性。在收敛方法中，首先通过使用混合酸酐法的高产率溶液相偶联制备了两个三肽片段Ac-Phe-Orn（Boc）-Pro-OH和Hd-Cha-Trp（For）-Arg-OEt偶联它们以得到线性六肽，在脱保护后，其可从市售氨基酸中以38％的总产率获得。HPLC纯化后，使用B

  DOI：

  10.1021/jo034228r

文献信息

• [EN] HETEROCYCLIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DE PROLINAMIDE
  申请人：INCEPTION 4 INC

  公开号：WO2017222915A1

  公开（公告）日：2017-12-28

  This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新颖的Formula (I)异环脯氨酰胺衍生物，以及在预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）和相关疾病中有用的药用盐、溶剂化合物、盐的溶剂化合物和其前药。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的退化的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中有用。本发明的化合物还可用于抑制眼睛或关节炎或相关疾病部位中的HTRAl蛋白酶活性。
• [EN] METHODS FOR TREATING MELANOMA USING SMALL MOLECULES AND SMALL INTERFERING RNA (SIRNA)<br/>[FR] PROCÉDÉS DE TRAITEMENT DE MÉLANOME À L'AIDE DE PETITES MOLÉCULES ET DE PETITS ARN INTERFÉRENTS (ARNSI)
  申请人：UNIV NOVA SOUTHEASTERN

  公开号：WO2018112443A1

  公开（公告）日：2018-06-21

  The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDXl (DDXl), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B 1). The invention additionally provides a method for identifying compounds active against melanoma cells.

  该发明提供了一种治疗癌症的方法，如黑色素瘤和/或转移性黑色素瘤，使用与细胞蛋白lamin A/C，ATP依赖性RNA解旋酶DDXl（DDXl），异质核糖核酸蛋白H1/H2（hnRNP H2）和/或异质核糖核酸蛋白A2/B1（hnRNP A2/B1）相互作用和/或抑制的化合物。该发明还提供了一种识别对黑色素瘤细胞有效的化合物的方法。
• [EN] DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)<br/>[FR] COMPOSÉS DITERPÉNOÏDES AGISSANT SUR LA PROTÉINE KINASE C (PKC)
  申请人：K GEN INC

  公开号：WO2021062030A1

  公开（公告）日：2021-04-01

  This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

  本公开涉及蛋白激酶C（PKC）调节化合物，使用这些化合物治疗癌症患者的方法，以及与第二治疗剂联合治疗的方法。
• [EN] ARYL AMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ARYLAMIDE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015006100A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• [EN] BORONIC ACID DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE ET LEURS UTILISATIONS
  申请人：INCEPTION 4 INC

  公开号：WO2016100555A1

  公开（公告）日：2016-06-23

  This invention is directed to novel Boronic acid derivatives of Formula I, and pharmaceutically acceptable salts, solvate, solvate of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of Age-related Macular Degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, Wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor ceils. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry -AMD, Wet- AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的化学式I的硼酸衍生物，以及在预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）老年性黄斑变性（AMD）及眼部相关疾病中有用的药用盐、溶剂化合物、盐的溶剂化合物和其前体。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRA1的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRA1介导的疾病中有用。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位中的HTRA1蛋白酶活性。